162 related articles for article (PubMed ID: 32461506)
1. Prediction of Sufficient Liver Enhancement on the Gadoxetate Disodium-enhanced Hepatobiliary Phase Imaging Using Transitional Phase Images and Albumin-bilirubin Grade.
Takatsu Y; Nakamura M; Kobayashi S; Miyati T
Magn Reson Med Sci; 2021 Jun; 20(2):152-159. PubMed ID: 32461506
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system.
Takatsu Y; Kobayashi S; Miyati T; Shiozaki T
Eur J Radiol; 2016 Dec; 85(12):2206-2210. PubMed ID: 27842668
[TBL] [Abstract][Full Text] [Related]
3. A novel method for evaluating enhancement using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid in the hepatobiliary phase of magnetic resonance imaging.
Takatsu Y; Kobayashi S; Miyati T; Shiozaki T
Clin Imaging; 2016; 40(6):1112-1117. PubMed ID: 27450444
[TBL] [Abstract][Full Text] [Related]
4. Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.
Aslan S; Eryuruk U; Tasdemir MN; Cakir IM
Abdom Radiol (NY); 2022 Jul; 47(7):2325-2334. PubMed ID: 35672474
[TBL] [Abstract][Full Text] [Related]
5. Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests.
Mori H; Machimura H; Iwaya A; Baba M; Furuya K
Sci Rep; 2021 Nov; 11(1):22472. PubMed ID: 34795343
[TBL] [Abstract][Full Text] [Related]
6. Visual criterion for evaluating hepatobiliary phase image acquisition of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced MRI.
Takatsu Y; Nakamura M; Kobayashi S; Miyati T
Clin Radiol; 2018 Aug; 73(8):760.e1-760.e6. PubMed ID: 29724434
[TBL] [Abstract][Full Text] [Related]
7. Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences.
Okubo H; Mogami M; Ozaki Y; Igusa Y; Aoyama T; Amano M; Kokubu S; Miyazaki A; Watanabe S
Hepatogastroenterology; 2013 Oct; 60(127):1547-51. PubMed ID: 23933786
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the cut-off value of quantitative liver-portal vein contrast ratio in the hepatobiliary phase of liver MRI.
Takatsu Y; Nakamura M; Shiozaki T; Narukami S; Yoshimaru D; Miyati T; Kobayashi S
Clin Radiol; 2021 Jul; 76(7):551.e17-551.e24. PubMed ID: 33902888
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of liver function using liver parenchyma, spleen and portal vein signal intensities during the hepatobiliary phase in Gd-EOB-D TPA-enhanced MRI.
Yang M; Zhang Y; Zhao W; Cheng W; Wang H; Guo S
BMC Med Imaging; 2020 Oct; 20(1):119. PubMed ID: 33081713
[TBL] [Abstract][Full Text] [Related]
10. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Kitamura T; Araki T
J Magn Reson Imaging; 2009 Nov; 30(5):1042-6. PubMed ID: 19856436
[TBL] [Abstract][Full Text] [Related]
11. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
Esterson YB; Flusberg M; Oh S; Mazzariol F; Rozenblit AM; Chernyak V
Clin Radiol; 2015 Jul; 70(7):723-9. PubMed ID: 25921617
[TBL] [Abstract][Full Text] [Related]
12. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
13. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI.
Ippolito D; Famularo S; Giani A; Orsini EB; Pecorelli A; Pinotti E; Gandola D; Romano F; Sironi S; Bernasconi DP; Gianotti L
Dig Liver Dis; 2019 Oct; 51(10):1438-1445. PubMed ID: 31153787
[TBL] [Abstract][Full Text] [Related]
14. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time?
Motosugi U; Ichikawa T; Tominaga L; Sou H; Sano K; Ichikawa S; Araki T
Eur Radiol; 2009 Nov; 19(11):2623-9. PubMed ID: 19471935
[TBL] [Abstract][Full Text] [Related]
15. Suboptimal hepatobiliary phase image in gadoxetic acid-enhanced liver MRI for the evaluation of the HCC: Predictive factors.
Ryeom H; Chang Y; Park SY; Cho SH; Yeo B; Je H; Baek J
Medicine (Baltimore); 2023 Nov; 102(46):e36176. PubMed ID: 37986292
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and Clinical Predictive Approach and Time Point Analysis of Hepatobiliary Phase Liver Enhancement on Gd-EOB-DTPA-enhanced MR Images: A Multicenter Study.
Okada M; Murakami T; Kuwatsuru R; Nakamura Y; Isoda H; Goshima S; Hanaoka R; Haradome H; Shinagawa Y; Kitao A; Fujinaga Y; Marugami N; Yuki M; Ichikawa T; Higaki A; Hori M; Fujii S; Matsui O
Radiology; 2016 Nov; 281(2):474-483. PubMed ID: 27195437
[TBL] [Abstract][Full Text] [Related]
17. Hepatic uptake index in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine penta acetic acid-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure.
Donadon M; Lanza E; Branciforte B; Muglia R; Lisi C; Pedicini V; Poretti D; Famularo S; Balzarini L; Torzilli G
Surgery; 2020 Sep; 168(3):419-425. PubMed ID: 32600880
[TBL] [Abstract][Full Text] [Related]
18. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
[TBL] [Abstract][Full Text] [Related]
19. Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement.
Matoori S; Froehlich JM; Breitenstein S; Pozdniakova V; Reischauer C; Kolokythas O; Koh DM; Gutzeit A
Eur Radiol; 2019 Nov; 29(11):5813-5822. PubMed ID: 31020338
[TBL] [Abstract][Full Text] [Related]
20. Predicting Patients With Insufficient Liver Enhancement in the Hepatobiliary Phase Before the Injection of Gadoxetic Acid: A Practical Approach Using the Bayesian Method.
Mori Y; Motosugi U; Shimizu T; Ichikawa S; Kromrey ML; Onishi H
J Magn Reson Imaging; 2020 Jan; 51(1):62-69. PubMed ID: 31016840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
